Amaria, Rodabe N. http://orcid.org/0000-0001-6876-278X
Postow, Michael
Burton, Elizabeth M.
Tetzlaff, Michael T.
Ross, Merrick I. http://orcid.org/0000-0002-7787-0421
Torres-Cabala, Carlos http://orcid.org/0000-0001-7422-0661
Glitza, Isabella C. http://orcid.org/0000-0002-4530-7765
Duan, Fei
Milton, Denái R.
Busam, Klaus http://orcid.org/0000-0003-0888-9601
Simpson, Lauren
McQuade, Jennifer L. http://orcid.org/0000-0002-2393-2172
Wong, Michael K.
Gershenwald, Jeffrey E.
Lee, Jeffrey E. http://orcid.org/0000-0001-6010-5590
Goepfert, Ryan P.
Keung, Emily Z.
Fisher, Sarah B.
Betof-Warner, Allison http://orcid.org/0000-0001-6422-2997
Shoushtari, Alexander N. http://orcid.org/0000-0002-8065-4412
Callahan, Margaret http://orcid.org/0000-0002-9087-0012
Coit, Daniel
Bartlett, Edmund K.
Bello, Danielle
Momtaz, Parisa
Nicholas, Courtney http://orcid.org/0000-0001-8596-0200
Gu, Aidi
Zhang, Xuejun
Korivi, Brinda Rao
Patnana, Madhavi http://orcid.org/0000-0001-8135-8001
Patel, Sapna P. http://orcid.org/0000-0003-1339-1517
Diab, Adi
Lucci, Anthony
Prieto, Victor G. http://orcid.org/0000-0001-9204-7161
Davies, Michael A. http://orcid.org/0000-0002-0977-0912
Allison, James P.
Sharma, Padmanee http://orcid.org/0000-0003-4658-055X
Wargo, Jennifer A. http://orcid.org/0000-0003-3438-7576
Ariyan, Charlotte
Tawbi, Hussein A. http://orcid.org/0000-0003-1942-851X
Article History
Received: 1 April 2022
Accepted: 20 September 2022
First Online: 26 October 2022
Change Date: 9 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-023-05892-1
Competing interests
: R.N.A.: research funding from Bristol-Myers Squibb, Iovance, Merck and Novartis; consulting role for Bristol-Myers Squibb, Iovance and Novartis. M. Postow: consulting fees from Aduro, Array BioPharma, Bristol-Myers Squibb, Eisai, Incyte, Merck, NewLink Genetics, Novartis and Pfizer; honoraria from Bristol-Myers Squibb and Merck; institutional support from Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Infinity, Merck, Novartis and RGenix. M.I.R.: clinical research funding from Amgen; consulting/advisory board member role for Amgen, Castle BioSciences, Merck and Novartis. I.C.G.: research funding from Bristol-Myers Squibb, Merck and Pfizer; consulting role for Bristol-Myers Squibb and Novartis. J.L.M.: honoraria for Bristol-Myers Squibb and Roche; consultant for Merck. M.K.W.: advisory boards for Adagene, Bristol-Myers Squibb, Castle Biosciences, EMD-Serono, ExiCure, Merck, Pfizer and Regeneron. J.E.G.: consultant and/or advisory role; Merck and Regeneron. A.N.S.: research funding from Bristol-Myers Squibb, Checkmate Pharmaceuticals, Foghorn Therapeutics, Immunocore, Novartis, Pfizer, Polaris, Targovax and Xcovery; advisory board for Bristol-Myers Squibb, Immunocore and Novartis. A.D.: research funding from Apexigen, Idera and Nektar; consulting for Apexigen, Idera, Memgen, Nektar and Pfizer. S.P.P.: research funding from Bristol-Myers Squibb, Ideaya and Provectus; consulting honoraria from Cardinal Health, Castle Biosciences and Merck. M.A.D.: consultant to ABM Therapeutics, Apexigen, Array, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Pfizer, Roche/Genentech, Novartis, Sanofi-Aventis and Vaccinex; PI of research grants to GlaxoSmithKline, MD Anderson by Roche/Genentech, Merck, Myriad, Oncothyreon and Sanofi-Aventis. J.P.A.: consulting or stock ownership or advisory board for Achelois, Adaptive Biotechnologies, Apricity, BioAtla, BioNTech, Candel Therapeutics, Codiak, Dragonfly, Earli, Enable Medicine, Hummingbird, ImaginAb, Jounce, Lava Therapeutics, Lytix, Marker, PBM Capital, Phenomic AI, Polaris Pharma, Time Bioventures, Trained Therapeutix and Venn Biosciences. P.S.: consulting or stock ownership or advisory board for Achelois, Adaptive Biotechnologies, Affini-T, Apricity, BioAtla, BioNTech, Candel Therapeutics, Catalio, Codiak, Constellation, Dragonfly, Earli, Enable Medicine, Glympse, Hummingbird, ImaginAb, Infinity Pharma, Jounce, JSL Health, Lava Therapeutics, Lytix, Marker, MedImmune, Oncolytics, PBM Capital, Phenomic AI, Polaris Pharma, Sporos, Time Bioventures, Trained Therapeutix and Venn Biosciences. J.A.W.: compensation for speaker’s bureau and honoraria from Bristol-Myers Squibb, Dava Oncology, Gilead, Illumina, Imedex, MedImmune, Omniprex, PeerView and Physician Education Resource; consultant/advisory board member for AstraZeneca, Biothera Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Micronoma, Novartis and Roche/Genentech. C.A.: consulting fees from Iovance. H.A.T.: research funding from GlaxoSmithKline; research funding and consulting honoraria from Bristol-Myers Squibb, Genentech, Merck and Novartis; consulting for Boxer, Eisai, Iovance, Karyopharm and Pfizer. All other authors report no conflicts of interest.